达格列净不损害2型糖尿病患者LDL分解代谢并改善VLDL1/VLDL2分解代谢
本研究为平行双盲活体动力学研究,使用稳定同位素在24例2型糖尿病患者中比较达格列净10mg/日与安慰剂治疗6个月对ApoB100脂蛋白代谢的影响。结果显示达格列净不改变LDL-ApoB100分解代谢,但显著降低VLDL1-ApoB100直接分解代谢并增加其向VLDL2和IDL的间接分解代谢,更接近正常生理。
要点
- 达格列净治疗6个月不损害2型糖尿病患者LDL分解代谢。
- 达格列净降低VLDL1直接分解代谢,增加VLDL1向VLDL2/IDL及VLDL2向IDL的间接分解代谢。
- 该代谢改善可能有助于解释SGLT2抑制剂减少动脉粥样硬化的作用。
核心结论
- 达格列净不损害2型糖尿病患者LDL分解代谢,并诱导VLDL1/VLDL2分解代谢向更接近正常的模式转变。
研究设计与样本
- 平行双盲活体动力学研究,使用稳定同位素(三氘标记L-亮氨酸)在24例2型糖尿病患者中于治疗前和治疗6个月后评估。
- 受试者随机接受达格列净10mg/日(n=17)或安慰剂(n=7),全部完成研究。
主要发现
- 与安慰剂组相比,达格列净组体重显著降低(p<0.001)且HbA1c显著降低(p=0.001)。
- 达格列净未显著改变血浆甘油三酯、LDL-胆固醇和ApoB100水平。
- 达格列净治疗后LDL-ApoB100分解代谢率无显著变化(0.88 ± 0.37 vs 0.79 ± 0.31 pool/day,p=0.16)。
- 达格列净显著降低VLDL1-ApoB100直接分解代谢(0.33 ± 0.65 vs 2.37 ± 2.31 pool/day,p=0.001)。
- 达格列净显著增加VLDL1-ApoB100向VLDL2和IDL的间接分解代谢(2.71 ± 1.51 vs 1.68 ± 1.46 pool/day,p=0.001)及VLDL2-ApoB100向IDL-ApoB100的间接分解代谢(3.57 ± 1.68 vs 2.64 ± 1.90 pool/day,p=0.049)。
临床怎么用
- 对于2型糖尿病患者,达格列净治疗不损害LDL分解代谢,可放心用于需关注LDL代谢的患者。
- 达格列净可能通过改善VLDL分解代谢途径发挥抗动脉粥样硬化作用。
局限性
- 研究样本量较小(达格列净组n=17,安慰剂组n=7)。
- 未报告其他潜在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: SGLT2 inhibitors reduce atherosclerosis, but their effect on lipid metabolism remains unclear. Animal studies have suggested that SGLT2 inhibitors may decrease LDL catabolism by reducing the hepatic expression of LDL receptors. However, the effect of SGLT2 inhibitors on LDL metabolism, and more widely on all ApoB-containing lipoproteins, remain unknown in humans. This prompted us to study the effect of the SGLT2 inhibitor dapagliflozin on the metabolism of ApoB100-containing lipoproteins in individuals with type 2 diabetes. METHODS: We performed a parallel double-blinded in vivo kinetic study using stable isotopes (tri-deuterated [2H3-labelled] L-leucine) in 24 individuals with type 2 diabetes before and after 6 months of treatment with dapagliflozin (10 mg/day) or placebo, given after randomisation. All individuals completed the study. RESULTS: Compared with placebo-treated individuals (n=7), those who received dapagliflozin (n=17) showed a significant reduction of body weight (p<0.001) and HbA1c (p=0.001). Plasma triglyceride, LDL-cholesterol and ApoB100 levels were not significantly modified by dapagliflozin treatment. LDL-ApoB100 fractional catabolism remained unchanged after dapagliflozin treatment (0.88 ± 0.37 vs 0.79 ± 0.31 pool/day, p=0.16). Similarly, no significant modification of the LDL-ApoB100 pool or LDL-ApoB100 production rate was observed. However, dapagliflozin induced a significant reduction in direct catabolism of VLDL1-ApoB100 (0.33 ± 0.65 vs 2.37 ± 2.31 pool/day, p=0.001) and a significant increase in the indirect catabolism of VLDL1-ApoB100 towards VLDL2 and IDL (2.71 ± 1.51 vs 1.68 ± 1.46 pool/day, p=0.001), and of VLDL2-ApoB100 towards IDL-ApoB100 (3.57 ± 1.68 vs 2.64 ± 1.90 pool/day, p=0.049), which is more representative of normal physiology. No significant side-effects were observed. CONCLUSIONS/INTERPRETATION: Dapagliflozin does not impair the catabolism of LDL in individuals with type 2 diabetes. It reduces direct catabolism of VLDL1 and increases indirect catabolism of VLDL1 towards VLDL2 and IDL, and of VLDL2 towards IDL, which is closer to normal metabolism. This may contribute to the reduction of atherosclerosis observed with use of SGLT2 inhibitors. TRIAL REGISTRATION: ClinicalTrials.gov NCT03269058 FUNDING: The study was funded via grants and support from AstraZeneca, the French National Research Agency (ANR) under the programme 'Investissements d'Avenir', the University of Burgundy-Franche-Comté, the National Institute of Health and Medical Research (Inserm), the Region Burgundy - Franche Comté, and the Fonds Européens de Développement Régional.
引用
- Vergès B, Rouland A, Bouillet B, et al. Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study. Diabetologia. 2026. PMID: 42467086. doi:10.1007/s00125-026-06810-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。